Table 3.
Responses to knowledge, attitude and behavior related questions.
| Questions | Agree (%) | Neutral (%) | Disagree (%) |
|---|---|---|---|
| Awareness of the National Pharmacovigilance Program in Oman | 95 (88.8) | 10 (9.3) | 2 (1.9) |
| Only ADRs to new drugs to be reported to the regulatory agency or drug company | 22 (20.5) | 21 (19.6) | 64 (59.8) |
| ADRs observed to topical agents need not be reported to the regulatory agency or drug company | 45 (42) | 10 (9.3) | 52 (48.6) |
| Reporting of ADRs adds up to existing knowledge of ADRs to old and new drugs | 93 (86.9) | 9 (8.4) | 5 (4.7) |
| Reporting of ADRs is a professional responsibility of the pharmacists | 97 (90.6) | 9 (8.4) | 1 (0.9) |
| Reporting of ADRs adds up to unnecessary workload | 12 (11.2) | 27 (25.2) | 68 (63.6) |
| Report ADRs to the regulatory agency in Oman/drug company | 74 (69.2) | 25 (23.4) | 8 (7.4) |
| Ask for the allergy history of the patient before dispensing the medication | 89 (83.2) | 18 (16.8) | 0 (0) |
| Inform the patient of the important side effects of the medications | 98 (91.5) | 7 (6.5) | 2 (1.9) |
| Inform patients of the methods to prevent ADRs of the dispensed medications | 93 (86.9) | 12 (11.2) | 2 (1.9) |